



University of
Pittsburgh®

School of
Public Health

PeerJ

Weighted multiple testing procedures in genome-wide association studies

Ludivine Obry and Cyril Dalmasso

Université Paris-Saclay, CNRS, Univ Evry, Laboratoire de Mathématiques et Modélisation d'Evry,
Evry-Courcouronnes, France

ABSTRACT

Multiple testing procedures controlling the false discovery rate (FDR) are increasingly used in the context of genome wide association studies (GWAS), and weighted multiple testing procedures that incorporate covariate information are efficient to improve the power to detect associations. In this work, we evaluate some recent weighted multiple testing procedures in the specific context of GWAS through a simulation study. We also present a new efficient procedure called wBHa that prioritizes the detection of genetic variants with low minor allele frequencies while maximizing the overall detection power. The results indicate good performance of our procedure compared to other weighted multiple testing procedures. In particular, in all simulated settings, wBHa tends to outperform other procedures in detecting rare variants while maintaining good overall power. The use of the different procedures is illustrated with a real dataset.

Subjects Bioinformatics, Genomics, Statistics, Data Science

Keywords False discovery rate, Genome wide association studies, Weighted MTP



Published in
PeerJ
June 15, 2023


Presentation by
Dylan Maher
HUGEN 2028
February 12, 2024



University of
Pittsburgh®

School of
Public Health

Reminder: Type I Error—false positive
Type II Error—false negative



Motivation

$$P(\text{Type I error}) = \alpha$$

$$P(\text{no Type I error}) = 1 - \alpha$$

$$P(\text{no Type I error in 1 test}) = (1 - \alpha)^1$$

$$P(\text{no Type I error in } n \text{ tests}) = (1 - \alpha)^n$$

$$P(\text{at least Type I error in } n \text{ tests}) = 1 - (1 - \alpha)^n$$

Marginal GWAS involves n
hypothesis tests ($n = \# \text{ SNPs}$)


SNPs on the order of millions to
tens of millions



University of
Pittsburgh®

School of
Public Health

Motivation



$$P(\text{at least Type I error in } n \text{ tests}) = 1 - (1 - \alpha)^n$$

Probability of making a Type I Error asymptotes at 1 (rather quickly!)

At 13 SNPs tested, the probability of at least one Type I Error is ~0.5

At 100 SNPs tested, it's ~0.995!



Two Main Classes of Solutions

Control
FWER

Control
FDR

Table 1 Outcomes for m tested hypotheses in a multiple testing situation.

	H_0 not rejected	H_0 rejected	Total
True H_0	TN	FP	m_0
False H_0 (True H_1)	FN	TP	m_1
	$W = m - R$	R	m

The **FWER** or **family-wise error rate** is the probability of at least one false positive:

$$FWER = P(FP > 0)$$

The **FDR** or **false-discovery rate** is the (expected) proportion of false positives to all positives (true and false):

$$FDR = E\left(\frac{FP}{TP + FP}\right)$$

al., 2017). While correlations between SNPs can substantially deteriorate the performance of many FDR procedures (Owen, 2005; Qiu, Klebanov & Yakovlev, 2005; Sarkar, 2006; Efron, 2007; Neuvial, 2008), the classical FDR procedures remain valid under different dependence assumptions (Benjamini & Yekutieli, 2001; Farcomeni, 2007; Wu et al., 2009).



Basic Idea

Two Main Classes of Solutions

FWER control:

↓
Make sure this number doesn't get too large

How many SNPs are we
going to incorrectly call
“significant”?

FDR control:

↓
Out of all the SNPs we call
“significant,” what
proportion will be
incorrect?



University of
Pittsburgh®

School of
Public Health

Motivation

Two Main Classes of Solutions

Traditionally, FWER (specifically, the Bonferroni method) is standard correction used in GWAS, however, as the author's claim:

Multiple testing procedures controlling the false discovery rate (FDR) are increasingly used in the context of genome wide association studies (GWAS), and weighted multiple

FDR has become increasingly popular

Control
FWER

Control
FDR

Is this true?



$$FWER = P(FP > 0)$$

$$FDR = E \left(\frac{FP}{TP + FP} \right)$$

**So, how can ensure
sufficient power while
maintaining acceptable
Type I error control?**

Motivation

FWER is more “stringent”

Why is this a concern specifically in
the context of GWAS?


2 main reasons—hints

- One is generic statistical concern
- The other is specific to studying genetics (think Bonferroni assumptions)



University of
Pittsburgh®

School of
Public Health



Motivation

Part of issue with power comes down to genetic architecture

In particular, high power is difficult to achieve with rare variants

Burden/collapsing tests aggregate variants and so sacrifice information on individual markers

Alternative solution is weighting strategies



University of
Pittsburgh®

School of
Public Health

Weighting

Idea behind weighting strategies:

Not all “hypotheses” (SNPs) are the same—some are more likely than others

Increase power for SNPs “more likely” to be associated at the expense of others that are “less likely”



The principle of weighted multiple testing procedures is to multiply the thresholds by weights (or equivalently the p -values or the test statistics by inverse weights) (*Holm, 1979; Benjamini & Hochberg, 1997; Genovese, Roeder & Wasserman, 2006*). Thus, the power increases for some individual hypotheses and it decreases for others, while keeping the error criterion control at an average weight equal to 1. In practice, most weighting procedures



University of
Pittsburgh®

School of
Public Health

Weighting

wBHa

Adaptive Techniques
(information
estimated from data)

Two Main
Classes of
Solutions

Control
FWER

Control
FDR

External
Information

have recently been introduced (*Ignatiadis et al., 2016; Zhang & Chen, 2020*). In a GWAS context, using the MAF as an informative covariate can help to detect rare variants.

What might be advantages/
disadvantages to each?



University of
Pittsburgh®

School of
Public Health

Method

The authors propose a method called wBHa:
weighted Benjamini-Hochberg (adaptive)

wBHa procedure

$$w(x_i, a) = \frac{m}{\sum_{j=1}^m \frac{1}{x_j^a}} \times \frac{1}{x_i^a}$$

Algorithm 1: *a* Optimization Algorithm

Input: A m -tuple of p -values $P = (p_1, \dots, p_m)$ and covariates $X = (x_1, \dots, x_m)$, a nominal level $\alpha \in (0, 1)$ for the FDR and a number of folds $K = 100$.

Output: Optimal a

for $k_i = 1, \dots, K$ **do**

 Sampling with replacement of $\frac{m}{K}$ hypotheses;

for $a = 0, 0.1, 0.2, \dots, 10$ **do**

 Application of wBH procedure at level α with $w(x_i, a) = \frac{m}{\sum_{j=1}^m \frac{1}{x_j^a}} \times \frac{1}{x_i^a}$;

 Computation and saving of the numbers of rejections R ;

end

 Saving the values a leading to the maximum of R in an ordered L -tuple ($L \geq 1$)

$A = (a_1, \dots, a_L)$;

if $L > 1$ **then**

 Computation of the successive differences in A ;

 Definition of interval bounds from differences larger to the step 0.1;

 Clustering of the L values of A within the v intervals thus defined;

if $v = 1$ **then**

 Saving the maximum value of the vector A ;

else

 Computation of the length of each interval;

if one of the intervals is longer than the others then

 Saving the maximum value in the longest interval;

else

 Saving the maximum value in the interval closest to 1;

end

end

end

end

Optimal a obtained by calculating the average of the K values;



University of
Pittsburgh®

School of
Public Health

Old-School BH

J. R. Statist. Soc. B (1995)
57, No. 1, pp. 289-300

Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing

By YOAV BENJAMINI† and YOSEF HOCHBERG

Tel Aviv University, Israel

[Received January 1993. Revised March 1994]

Original method proposed
by Benjamini and
Hochberg

Basic idea:

1. Rank order p-values (smallest to largest)
2. Multiply them by

$$\frac{i}{m} \leftarrow \begin{array}{l} \text{rank} \\ \# \text{ of p-values} \end{array}$$

3. Call new value p^*
4. Reject null if

$$p^* < \alpha$$



University of
Pittsburgh®

School of
Public Health

False discovery control with p -value weighting

BY CHRISTOPHER R. GENOVESE, KATHRYN ROEDER
AND LARRY WASSERMAN

*Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213,
U.S.A.*

Method was extended in
2005 by Genovese,
Roeder, and Wasserman
(right down the street!)

wBH

Basic idea:

1. Assign each null hypothesis $H_{0,i}$ a non-negative weight

$$w_i : \sum_{i=1}^m w_i = m$$

2. Apply BH but replace each p-value with new p-value:

$$p_i = \frac{p_i}{w_i}$$




University of
Pittsburgh®

School of
Public Health

wBHa

Sidenote: “**bagging**”
(**bootstrap aggregating**)

1. Create bootstrap samples (sample w/ replacement)
2. Use samples to predict outcome
3. Aggregate outcomes





wBHa procedure

$$w(x_i, a) = \frac{m}{\sum_{j=1}^m \frac{1}{x_j^a}} \times \frac{1}{x_i^a}$$

Assign more “weight” (importance) to hypotheses testing rare variants

wBHa

Weight varies as a function of MAF
(and a)

Two steps:

1. Determine optimal a (maximizes H_0 rejections over grid of values)
2. Apply weighted BH

Use bagging to prevent overfitting,
take average a over “bags”

Procedure can be used with any
covariate, MAF used as example



Simulation Study: Genotypes

Genotype matrix: $G_{n \times m}$,
 $n = 2000$,
 $m \in \{8000, 14000, 200000\}$,
 $G_{ij} \in \{0, 1, 2\}$,
 $G_i^* \sim N_m(0, \Sigma)$
 $\Sigma \sim \text{blkdiag}(\Sigma_1, \Sigma_2, \dots, \Sigma_k)$
blocks size 10, equicorrelated at ρ
 $\rho \in \{0, 0.1, 0.2, 0.3, 0.35, 0.5, 0.75\}$

MAF (causal) divided into four groups with uniforms

- $U[0.01, 0.05]$ $G_{ij} = 2$ if $q_r < \Phi^{-1}(0, 1)$
- $U[0.05, 0.15]$ $G_{ij} = 1$ if $q_r < \Phi^{-1}(1 - p, 0.1) < q_r$
- $U[0.15, 0.25]$ $G_{ij} = 0$ if $q_r < \Phi^{-1}(p^2, 0.1) < q_r$
- $U[0.30, 0.40]$

The number of causal SNPs (m_1): $\{5, 10, 15, 20, 25, 50, 100, 150\}$

Three scenarios for β_j :

- rare causal variants have greater effects
- common variants have greater effects
- all β_j are equal

“Medium-rare” SNPs (hehe)



University of
Pittsburgh®

School of
Public Health

Quantitative

$$Y_i = \sum_{j=1}^m \beta_j G_{ij} + \varepsilon_i, \quad \varepsilon_i \sim \mathcal{N}(0, \sigma^2)$$

$$\sigma_i^2 = \frac{(R^2 - 1) \sum (G_{ijj} - \bar{Y}_i)^2}{R^2(2 - n)} \quad \text{set } R^2 = 0.2$$


Case-control

$$P(Y_i = 1 | \mathbf{G}_i) = \frac{e^{\beta_0 + \sum_j \beta_j G_{ij}}}{1 + e^{\beta_0 + \sum_j \beta_j G_{ij}}}$$

Simulation Study: Phenotypes

Table 2 Values of effect sizes (β) of SNPs for quantitative and binary traits into three scenarios.

		Non causal SNP	Rare causal SNP	Medium-Rare causal SNP	Medium causal SNP	Common causal SNP
Quantitative Trait	Scenario 1	0	4	3	2	1
	Scenario 2	0	1	2	3	4
	Scenario 3	0	2	2	2	2
Binary Trait	Scenario 1	0	log(2.2)	log(1.8)	log(1.5)	log(1.3)
	Scenario 2	0	log(1.3)	log(1.5)	log(1.8)	log(2.2)
	Scenario 3	0	log(1.5)	log(1.5)	log(1.5)	log(1.5)





University of
Pittsburgh® | School of
Public Health

**The Search for Host Genetic Factors of HIV/AIDS
Pathogenesis in the Post-Genome Era:
Progress to Date and New Avenues for Discovery**

Bradley E. Aouizerat • C. Leigh Pearce •
Christine Miaskowski

307,851 SNPs
605 individuals

MAF bins

[0.01,0.05]: 558
[0.05,0.15]: 4909
[0.15,0.30]: 6674
[0.30,1.00]: 7840

Simulation based on Real Dataset

To simulate effect sizes:
Estimated coefficients with wBH
Let effect size = absolute value of
quartiles

Three effect size scenarios

1. Rare < Common
2. Common < Rare
3. All equal



Simulation Evaluation

Table 3 Procedures compared.

Procedure	R package	Function	Version	Reference
BH	stats	p.adjust	4.2.1	<i>Benjamini & Hochberg (1995)</i>
qvalue	qvalue	qvalue	2.28.0	<i>Storey & Tibshirani (2003)</i>
FDRreg	FDRreg	FDRreg	0.2.1	<i>Scott et al. (2015)</i>
swfdr	swfdr	lm_qvalue	1.22.0	<i>Boca & Leek (2018)</i>
IHW	ihw	ihw	1.24.0	<i>Ignatiadis et al. (2016)</i>
CAMT	CAMT	camt.fdr	1.1	<i>Zhang & Chen (2020)</i>

Average power
(over 500 iterations)

$$E \left(\frac{TP}{m_1} \right)$$

Average power
(by subgroup)

$$E \left(\frac{TP_g}{m_{1g}} \right), g = 1, 2, 3, 4$$

Table 1 Outcomes for m tested hypotheses in a multiple testing situation.

	H_0 not rejected	H_0 rejected	Total
True H_0	TN	FP	m_0
False H_0 (True H_1)	FN	TP	m_1
	$W = m - R$	R	m




**School of
Public Health**

Simulation Results

m_1 = # of causal SNPs

Overall power comparison in scenario 1, with simulations based on real data, for different m_1 values.


Power comparison in subgroup of rare variants in scenario 1, with simulations based on real data, for different m_1 values.






Simulation Results

FDR (independent markers)



FDR (correlated markers)



Real Dataset

Gene Expression
Omnibus (GEO)
database

***LRRK2* but not *ATG16L1* is associated with Paneth cell defect in Japanese Crohn's disease patients**


Ta-Chiang Liu,¹ Takeo Naito,² Zhenqiu Liu,³ Kelli L. VanDussen,¹ Talin Haritunians,³ Dalin Li,³ Katsuya Endo,² Yosuke Kawai,⁴ Masao Nagasaki,⁴ Yoshitaka Kinouchi,⁵ Dermot P.B. McGovern,³ Tooru Shimosegawa,² Yoichi Kakuta,² and Thaddeus S. Stappenbeck¹

659,636 SNPs (607,720 after QC)

98 individuals

Paneth cell phenotype (small intestine)


Crohn's Disease




Note that while wBHa is not the most powerful procedure, it identified six specific SNPs (Fig. 8) that could not be selected by the other procedures. Interestingly, two of these SNPs, *rs3772479* and *rs2270569*, are located in the *FHIT* and *KIF9* genes, respectively, which have been reported to play an important role in inflammatory bowel disease (IBD) (Crohn's disease being a type of IBD) (*Skopelitou et al., 2003; Xu & Qiao, 2006; Wierzbicki et al., 2009; Wang et al., 2018*).



Real Dataset Results



Rejected SNPs by MAF



Selected SNPs



University of
Pittsburgh®

School of
Public Health

Discussion

Some main takeaways

- wBHa performed well in simulations, good overall power
- IHW & CAMT perform better as proportion of non-null hypotheses increases
- wBH most powerful in all scenarios with rare variants
- In real data analysis, wBHa identified six SNPs undiscoverable by other methods

“Our new procedure wBHa, which showed good performance in all settings, appears to be a good choice for prioritizing rare variants without loss of power.”

Do we agree?

Authors:


In conclusion, adaptive weighted multiple testing procedures based on informative covariates show great promise in the context of genome-wide association studies. Our new



University of
Pittsburgh®

School of
Public Health

Further Info



zenodo

R package
`install.packages("wBHa")`

GitHub repositories available

Zenodo projects archived

Supplemental Information &
Author/Reviewer
correspondence available on
PeerJ

AVAILABILITY

The wBHa procedure is implemented in the R package wBHa which is available at <https://github.com/obryludivine/wBHa>. A second GitHub repository is also available at https://github.com/obryludivine/wBHa_simulation. It contains the programs used to create the simulated datasets and allows our results to be reproduced. These projects have been archived on Zenodo on <https://zenodo.org/badge/latestdoi/409590338> and <https://zenodo.org/badge/latestdoi/402729574> respectively.



University of
Pittsburgh® | School of
Public Health

FIN.

